Access Point Medical, LLC v. Mandell

106 A.D.3d 40, 963 N.Y.S.2d 44

This text of 106 A.D.3d 40 (Access Point Medical, LLC v. Mandell) is published on Counsel Stack Legal Research, covering Appellate Division of the Supreme Court of the State of New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Access Point Medical, LLC v. Mandell, 106 A.D.3d 40, 963 N.Y.S.2d 44 (N.Y. Ct. App. 2013).

Opinion

OPINION OF THE COURT

Saxe, J.

Plaintiffs Access Point Medical, LLC and its wholly owned [42]*42subsidiary, Access Point Medical, Inc., were formed by nonparty Bill Kidd, with the assistance of defendant attorney Edward R. Mandell, to engage in the business of manufacturing and selling durable home medical equipment such as wheelchairs, canes, walkers, and oxygen tanks. Kidd was plaintiffs’ largest shareholder and served as chairman of the board. In this action, plaintiffs essentially allege that defendants, acting as their attorneys, actively misled them and failed to disclose critical information because, while representing them, defendants simultaneously represented Kidd when Kidd’s interests were adverse to theirs.

Plaintiffs commenced this action on February 17, 2010, alleging causes of action for legal malpractice, breach of contract, and breach of fiduciary duty, and seeking damages including compensatory damages and the “disgorgement” of the $658,117.68 they paid to defendants in legal fees. In support of these causes of action, the complaint alleges a number of events. First, that Mandell and his law firm, defendant Troutman Sanders, LHP, prepared the private placement memoranda when Kidd decided to sell plaintiffs’ securities to outside investors in order to recoup his investment, and errors in those memoranda exposed plaintiffs to legal liability. Second, that defendants improperly represented both Kidd and plaintiffs in the drafting and negotiating of a management services agreement between them, despite, and without disclosing, the existence of a conflict between their interests.

Plaintiffs further allege that defendants negotiated a line of credit for them from Wells Fargo, while failing to address Kidd’s causing or contributing to their deteriorating financial condition and the certainty of their default on the line of credit, rendering them liable for extra penalties and fees and, ultimately, causing the cancellation of the line of credit. In addition, plaintiffs claim that defendants failed to properly inform them of warning letters sent by the Food and Drug Administration regarding allegedly defective products being sold by them, resulting in loss of business and damage to their business reputation.

Defendants’ motion to dismiss the complaint pursuant to CPLR 3211 (a) (1) and (7) was granted (2011 NY Slip Op 32107 [2011]). The motion court observed that the claims for malpractice and breach of fiduciary duty were barred by the three-year statute of limitations (CPLR 214), because all the complained-of [43]*43conduct occurred in 2005 or 2006. As to the language added in plaintiffs’ amended complaint, that “[u]pon information and belief, Troutman’s and Mandell’s representation of APM continued through March 2007,” the motion court found that it was conclusively disproved by the last entry on defendants’ final invoice to plaintiffs, which reflects a telephone call on February 14, 2007, more than three years before this action was commenced.

Plaintiffs do not challenge the motion court’s determination that their legal malpractice action was barred by the three-year statute of limitations, since the cause of action accrued in 2005 or 2006, this action was commenced on February 17, 2010, and the continuous representation doctrine was not shown to be applicable. However, they challenge the ruling that their breach of fiduciary duty claims are also barred by the three-year limitations period.

Plaintiffs’ argument against treating the fiduciary duty claims as time-barred has changed over time. They acknowledged before the motion court that the three-year limitations period applied to the breach of fiduciary duty claims, but insisted that under the continuous representation doctrine the fiduciary duty claims did not start to run until some time after March 2007. Now plaintiffs take the position that it is the six-year statute of limitations that applies to their claims for breach of fiduciary duty.

For breach of fiduciary duty claims, “the choice of the applicable limitations period depends on the substantive remedy that the plaintiff seeks” (IDT Corp. v Morgan Stanley Dean Witter & Co., 12 NY3d 132, 139 [2009]). Plaintiffs characterize their claim, seeking the return of $658,117.68 that they paid in attorneys’ fees, as an equitable claim for “disgorgement,” to which they contend the six-year limitations period should apply. However, we reject plaintiffs’ contention that the remedy they seek is properly characterized as an equitable claim for disgorgement.

Plaintiffs rely on this Court’s statement that “[d]isgorgement is an equitable remedy” (see J.P. Morgan Sec. Inc. v Vigilant Ins. Co., 91 AD3d 226, 230 [1st Dept 2011], lv granted 19 NY3d 806 [2012]). However, the disgorgement remedy referred to in J.P. Morgan Sec. and the cases it discusses is fundamentally different than the “disgorgement” plaintiff seeks here. Claims for disgorgement most commonly arise in actions brought by the Securities and Exchange Commission in which the agency seeks [44]*44an order directing a party to disgorge its ill-gotten gains for the recompense of injured investors or some entity other than the prosecuting agency (see J.P. Morgan Sec. Inc. v Vigilant Ins. Co., 91 AD3d 226, 230 [2011] and cases discussed therein). Other types of government agencies or quasi-governmental entities also have sought the disgorgement of wrongfully obtained funds to third parties (see e.g. Morgan Stanley Capital Group Inc. v Public Util. Dist. No. 1 of Snohomish Cty., 554 US 527, 538 [2008]; Montana v Crow Tribe, 523 US 696 [1998]). Similarly, the equitable disgorgement relief sought by the plaintiff in IDT Corp. v Morgan Stanley Dean Witter & Co. (12 NY3d at 139) consisted of profits Morgan Stanley allegedly earned as investment banker for a third party through the third party’s allegedly improper financial dealings with IDT; consequently, the disgorgement of those profits could not necessarily be accomplished simply by awarding IDT a judgment against Morgan Stanley in the amount of funds that it had paid out.

In contrast, plaintiffs’ demand for the return of attorneys’ fees they paid to defendants is, essentially, a claim for monetary damages. The calculated use of the term “disgorgement” instead of other equally applicable terms such as repayment, recoupment, refund, or reimbursement, should not be permitted to distort the nature of the claim so as to expand the applicable limitations period from three years to six. We cannot allow a purely semantic distinction to control the application of the statute of limitations.

Nor do we accept plaintiffs’ alternative argument that the breach of fiduciary duty claim is essentially a fraud claim, to which the six-year statute would be applicable. The amended complaint is based on an alleged conflict of interest and allegedly impaired professional judgment, and it does not allege the elements of fraud (see Buller v Giorno, 57 AD3d 216 [1st Dept 2008]). The failure to disclose a conflict of interest does not transform a breach of fiduciary duty into a fraud.

Another new contention plaintiffs raise on appeal is that the statute of limitations must be treated as tolled, not only pursuant to the continuous representation doctrine, but also under the fiduciary tolling rule, also known as the open repudiation rule.

As the motion court found, no facts are alleged that would justify the application of the continuous representation doctrine to toll the statute of limitations.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Montana v. Crow Tribe of Indians
523 U.S. 696 (Supreme Court, 1998)
IDT Corp. v. Morgan Stanley Dean Witter & Co.
907 N.E.2d 268 (New York Court of Appeals, 2009)
In Re the Estate of Ashheim
78 N.E. 1099 (New York Court of Appeals, 1906)
In re the Estate of Ashheim
111 A.D. 176 (Appellate Division of the Supreme Court of New York, 1906)
In re the Estate of Barabash
286 N.E.2d 268 (New York Court of Appeals, 1972)
212 Investment Corp. v. Kaplan
44 A.D.3d 332 (Appellate Division of the Supreme Court of New York, 2007)
Buller v. Giorno
57 A.D.3d 216 (Appellate Division of the Supreme Court of New York, 2008)
J.P. Morgan Securities Inc. v. Vigilant Insurance
91 A.D.3d 226 (Appellate Division of the Supreme Court of New York, 2011)
Westchester Religious Institute v. Kamerman
262 A.D.2d 131 (Appellate Division of the Supreme Court of New York, 1999)
Kaszirer v. Kaszirer
286 A.D.2d 598 (Appellate Division of the Supreme Court of New York, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
106 A.D.3d 40, 963 N.Y.S.2d 44, Counsel Stack Legal Research, https://law.counselstack.com/opinion/access-point-medical-llc-v-mandell-nyappdiv-2013.